Research Analysts Offer Predictions for TENX Q1 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Tenax Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Phipps forecasts that the specialty pharmaceutical company will post earnings per share of ($0.23) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.34.

Several other research analysts have also weighed in on the company. StockNews.com began coverage on Tenax Therapeutics in a research report on Saturday. They issued a “sell” rating for the company. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $6.49 on Thursday. The stock has a market cap of $25.73 million, a price-to-earnings ratio of -1.22 and a beta of 2.20. The firm has a 50 day simple moving average of $6.43 and a 200-day simple moving average of $5.42. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new stake in Tenax Therapeutics during the 4th quarter worth approximately $84,000. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics during the third quarter worth $101,000. Geode Capital Management LLC increased its position in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the period. Millennium Management LLC acquired a new stake in shares of Tenax Therapeutics in the fourth quarter valued at $166,000. Finally, Stonepine Capital Management LLC purchased a new position in Tenax Therapeutics in the third quarter valued at $173,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.